Completed PHASE2 INTERVENTIONAL 1-arm NCT00468403

LEA29Y (Belatacept) Emory Edmonton Protocol (LEEP)

Islet Transplantation in Type I Diabetes With LEA29Y (Belatacept) Maintenance Therapy (CIT-04)

Sponsor: Clinical Islet Transplantation Consortium

Interventions Allogeneic Pancreatic Islet Cells Basiliximab Belatacept Intraportal infusion of islet cells Mycophenolate Mofetil Tacrolimus

Updated 7 times since 2017 Last updated: Mar 9, 2016 Started: Oct 31, 2008 Primary completion: Apr 30, 2012 Completion: Apr 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Type 1 Diabetes Mellitus, this trial is completed. The trial is conducted by Clinical Islet Transplantation Consortium and has accumulated 7 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinical Islet Transplantation Consortium
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States
• Edmonton, Canada